Drug transport to brain with targeted nanoparticles
Open accessThe DOI matches its Crossref record; 150 of the 150 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biodegradable polymeric nanoparticles as drug delivery devices
Soppimath, K. S., Aminabhavi, T. M., Kulkarni, A. R., & Rudzinski, W. E. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(00)00339-4 · Cited by 3,549 · cited 1×
“ration technique or the precipitation solvent diffusion technique.(1) In the first method, copolymers are dissolved in an organic solvent immiscible to water (such as di-”
MethodLong-Circulating and Target-Specific Nanoparticles: Theory to Practice
Moghimi, S. M., Hunter, A. C., & Murray, J. C. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01494-7 · Cited by 3,515
Biodegradable nanoparticles for drug and gene delivery to cells and tissue
Panyam, J., & Labhasetwar, V. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00228-4 · Cited by 3,361
Biodegradable Long-Circulating Polymeric Nanospheres
Gref, R., Minamitake, Y., Peracchia, M. T., Trubetskoy, V., Torchilin, V., & Langer, R. (1994) · Science · doi:10.1126/science.8128245 · Cited by 2,920
Biodegradation and biocompatibility of PLA and PLGA microspheres
Anderson, J. M., & Shive, M. S. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(97)00048-3 · Cited by 2,617 · cited 2×
“ular weight, the lactic/glycolic ratio, and the morphology), amount of water absorbed, diffusion coefficient of the polymer fragments through the polymer matrix, and solubility of the degradation products in the surrounding aqueous medium.(40,41) All of these parameters are influenced by temperature, additives (includ…”
BackgroundGref, R., Lück, M., Quellec, P., Marchand, M., Dellacherie, E., Harnisch, S., Blunk, T., & Müller, R. H. (2000) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/s0927-7765(99)00156-3 · Cited by 1,723
Chemistry for peptide and protein PEGylation
Roberts, M. J., Bentley, M. D., & Harris, J. M. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00022-4 · Cited by 1,604
Solid lipid nanoparticles for parenteral drug delivery
Wissing, S. A., Kayser, O., & Müller, R. H. (2004) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2003.12.002 · Cited by 1,495
Moghimi, S. M., & Szebeni, J. (2003) · Progress in Lipid Research · doi:10.1016/s0163-7827(03)00033-x · Cited by 1,227
Nanoparticulate systems for brain delivery of drugs.
Kreuter, J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00122-8 · Cited by 1,107 · cited 2×
“incubation in citrate-stabilized plasma at 37°C, but not on nanoparticles coated with poloxamers 338, 407, Cremophor EL, or RH 40.(29) Despite numerous arguments listed by Kreuter,(29) this hypothesis raises questions, based on the following observations.”
Background
Cited by
Nanoparticle-based targeted drug delivery
Singh, R., & Lillard, J. W. (2009) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2008.12.004 · Cited by 2,734
Aggarwal, P., Hall, J. B., McLeland, C. B., Dobrovolskaia, M. A., & McNeil, S. E. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.03.009 · Cited by 1,791
Mohanraj, V. J., & Chen, Y. (2007) · Tropical Journal of Pharmaceutical Research · doi:10.4314/tjpr.v5i1.14634 · Cited by 1,217
Nanotechnology: Intelligent Design to Treat Complex Disease
Couvreur, P., & Vauthier, C. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-0284-8 · Cited by 948
New emerging trends in synthetic biodegradable polymers—Polylactide: A critique
Gupta, A. P., & Kumar, V. (2007) · European Polymer Journal · doi:10.1016/j.eurpolymj.2007.06.045 · Cited by 941
Current advances in research and clinical applications of PLGA-based nanotechnology
Lü, J.-M., Wang, X., Marin-Muller, C., Wang, H., Lin, P. H., Yao, Q., & Chen, C. (2009) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.09.15 · Cited by 903
Approaches to transport therapeutic drugs across the blood–brain barrier to treat brain diseases
Gabathuler, R. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.07.028 · Cited by 802
Overcoming the Blood–Brain Barrier: The Role of Nanomaterials in Treating Neurological Diseases
Furtado, D., Björnmalm, M., Ayton, S., Bush, A. I., Kempe, K., & Caruso, F. (2018) · Advanced Materials · doi:10.1002/adma.201801362 · Cited by 708
Mahapatro, A., & Singh, D. K. (2011) · Journal of Nanobiotechnology · doi:10.1186/1477-3155-9-55 · Cited by 685
Potential of solid lipid nanoparticles in brain targeting.
Kaur, I. P., Bhandari, R., Bhandari, S., & Kakkar, V. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.12.018 · Cited by 615
Core/shell nanoparticles in biomedical applications
Chatterjee, K., Sarkar, S., Jagajjanani Rao, K., & Paria, S. (2014) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2013.12.008 · Cited by 610
Nanoparticle decoration with surfactants: Molecular interactions, assembly, and applications
Heinz, H., Pramanik, C., Heinz, O., Ding, Y., Mishra, R. K., Marchon, D., Flatt, R. J., Estrela-Lopis, I., Llop, J., Moya, S., et al. (2017) · Surface Science Reports · doi:10.1016/j.surfrep.2017.02.001 · Cited by 608
Blood–Brain Barrier Transport of Therapeutics via Receptor-Mediation
Jones, A. R., & Shusta, E. V. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9379-0 · Cited by 549
Microparticles and nanoparticles for drug delivery
Kohane, D. S. (2007) · Biotechnology and Bioengineering · doi:10.1002/bit.21301 · Cited by 517
Bhaskar, S., Tian, F., Stoeger, T., Kreyling, W., de la Fuente, J. M., Grazú, V., Borm, P., Estrada, G., Ntziachristos, V., & Razansky, D. (2010) · Particle and Fibre Toxicology · doi:10.1186/1743-8977-7-3 · Cited by 495
Hersh, A. M., Alomari, S., & Tyler, B. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084153 · Cited by 478
“PEG is considered a “stealth” molecule and provides a longer window of opportunity for the NPs to interact with endothelial receptors [48,49].”
BackgroundWhat do we (need to) know about the kinetic properties of nanoparticles in the body?
Hagens, W. I., Oomen, A. G., de Jong, W. H., Cassee, F. R., & Sips, A. J. A. M. (2007) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2007.07.006 · Cited by 464
Aryal, M., Arvanitis, C. D., Alexander, P. M., & McDannold, N. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.01.008 · Cited by 443
Active targeting of brain tumors using nanocarriers
Béduneau, A., Saulnier, P., & Benoit, J.-P. (2007) · Biomaterials · doi:10.1016/j.biomaterials.2007.06.011 · Cited by 424
Harush-Frenkel, O., Rozentur, E., Benita, S., & Altschuler, Y. (2008) · Biomacromolecules · doi:10.1021/bm700535p · Cited by 405
The blood-brain barrier: structure, function and therapeutic approaches to cross it.
Tajes, M., Ramos-Fernández, E., Weng-Jiang, X., Bosch-Morató, M., Guivernau, B., Eraso-Pichot, A., Salvador, B., Fernàndez-Busquets, X., Roquer, J., & Muñoz, F. J. (2014) · Molecular Membrane Biology · doi:10.3109/09687688.2014.937468 · Cited by 380
Nanovehicular Intracellular Delivery Systems
Prokop, A., & Davidson, J. M. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21270 · Cited by 363
Han, L., & Jiang, C. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.11.023 · Cited by 358
Gold Nanoparticles as Contrast Agents in x-ray Imaging and Computed Tomography
Cole, L. E., Ross, R. D., Tilley, J. M., Vargo-Gogola, T., & Roeder, R. K. (2015) · Nanomedicine · doi:10.2217/nnm.14.171 · Cited by 356
Hu, K., Li, J., Shen, Y., Lu, W., Gao, X., Zhang, Q., & Jiang, X. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.10.016 · Cited by 354
Biocompatibility and Toxicity of Nanoparticles and Nanotubes
Li, X., Wang, L., Fan, Y., Feng, Q., & Cui, F.-Z. (2012) · Journal of Nanomaterials · doi:10.1155/2012/548389 · Cited by 351
Applications of nanotechnology in drug delivery to the central nervous system
Saeedi, M., Eslamifar, M., Khezri, K., & Dizaj, S. M. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.12.133 · Cited by 342
Nanoparticles: Functionalization and Multifunctional Applications in Biomedical Sciences
Subbiah, R., Veerapandian, M., & S. Yun, K. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710794183024 · Cited by 327
Solid Lipid Nanoparticles (SLNs): An Advanced Drug Delivery System Targeting Brain through BBB
Satapathy, M. K., Yen, T.-L., Jan, J.-S., Tang, R.-D., Wang, J.-Y., Taliyan, R., & Yang, C.-H. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13081183 · Cited by 318
“If the hydrophobic nature of the nanoparticle containing the drug can be shielded, it will be sterically stabilized, thus avoiding opsonization, and further increasing the blood circulation time and hence the bioavailability [101].”
Alginate Nanoparticles for Drug Delivery and Targeting
Severino, P., da Silva, C. F., Andrade, L. N., de Lima Oliveira, D., Campos, J., & Souto, E. B. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190425163424 · Cited by 304
Nanotechnology applied to overcome tumor drug resistance
Gao, Z., Zhang, L., & Sun, Y. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.05.051 · Cited by 303
Chen, L., Yokel, R. A., Hennig, B., & Toborek, M. (2008) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-008-9131-5 · Cited by 293
Nanoparticle‐Mediated Drug Delivery and Gene Therapy
Jin, S., & Ye, K. (2007) · Biotechnology Progress · doi:10.1021/bp060348j · Cited by 283
Delivery of peptide and protein drugs over the blood–brain barrier
Brasnjevic, I., Steinbusch, H. W. M., Schmitz, C., & Martinez-Martinez, P. (2009) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2008.12.002 · Cited by 279
Nanocarriers for the treatment of glioblastoma multiforme: Current state-of-the-art
Karim, R., Palazzo, C., Evrard, B., & Piel, G. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.02.026 · Cited by 252
Potential neurotoxicity of nanoparticles
Hu, Y.-L., & Gao, J.-Q. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.04.026 · Cited by 213
Nanoscale drug delivery systems and the blood–brain barrier
Khalin, I., Alyautdin, R., Ismail, N. M., Haron, M. H., & Kuznetsov, D. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s52236 · Cited by 204
Past, Present, and Future Technologies for Oral Delivery of Therapeutic Proteins
Singh, R., Singh, S., & Lillard, J. W. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21183 · Cited by 186
Nanotheranostics: Emerging Strategies for Early Diagnosis and Therapy of Brain Cancer
Sonali, Viswanadh, M. K., Singh, R. P., Agrawal, P., Mehata, A. K., Pawde, D. M., Narendra, Sonkar, R., & Muthu, M. S. (2018) · Nanotheranostics · doi:10.7150/ntno.21638 · Cited by 169
“Using anti-transcytosis receptor peptidomimetic antibodies to BBB, brain glioma targeted PEGylated immune nanoparticles were prepared which able to deliver the anti-cancer agents into brain parenchyma without BBB permeability alteration [111, 117].”
MethodTheranostic applications of nanoparticles in neurodegenerative disorders
Ramanathan, S., Archunan, G., Sivakumar, M., Tamil Selvan, S., Fred, A. L., Kumar, S., Gulyás, B., & Padmanabhan, P. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s149022 · Cited by 161
“The walls of capillaries present in the BBB separate the brain from circulating blood.(12,13) Figure 1 shows the various mechanisms of transport across the BBB.”
Dufès, C., Al Robaian, M., & Somani, S. (2013) · Therapeutic Delivery · doi:10.4155/tde.13.21 · Cited by 110
Nanoparticles as Blood–Brain Barrier Permeable CNS Targeted Drug Delivery Systems
Grabrucker, A. M., Chhabra, R., Belletti, D., Forni, F., Vandelli, M. A., Ruozi, B., & Tosi, G. (2013) · Topics in Medicinal Chemistry · doi:10.1007/7355_2013_22 · Cited by 53
Metadata
- Authors
- Olivier, J.-C.
- Venue
- NeuroRX
- Published
- 2005-01
- Volume
- 2
- Issue
- 1
- Pages
- 108-119
- ISSN
- 1545-5343 (ISSN-L)
- OpenAlex
- W2068491059
- Cited by
- 444
- References
- 150
- FWCI
- 7.76
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.